🟢 NanoViricides is trading 6.54% up today after Phase II MPox trial enrollment began

NanoViricides is trading 6.54% up at $1.63; on September 23, 2026, it announced that enrollment of the first patients began in its Phase II NV-387 trial for MPox in the Democratic Republic of Congo.

• The trial evaluates oral gummies against standard of care.
• This is NV-387’s first Phase II study. The announcement did not report trading volume or explicitly link the news to the share-price move.